What is Nu-Med Plus Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nu-Med Plus's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.06.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Nu-Med Plus couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Nu-Med Plus's Cash-to-Debt or its related term are showing as below:
NUMD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.33 Max: No Debt
Current: 0.06
During the past 13 years, Nu-Med Plus's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.33.
Nu-Med Plus Cash-to-Debt Historical Data
The historical data trend for Nu-Med Plus's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Nu-Med Plus Cash-to-Debt Chart
|
Nu-Med Plus Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.03 |
11.12 |
1.50 |
0.73 |
0.07 |
|
Nu-Med Plus Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.53 |
0.30 |
0.11 |
0.07 |
0.06 |
Competitive Comparison of Nu-Med Plus's Cash-to-Debt
For the Medical Devices subindustry, Nu-Med Plus's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's Cash-to-Debt falls into.
Nu-Med Plus Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Nu-Med Plus's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Nu-Med Plus's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus (Nu-Med Plus) Business Description
Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
| William C Hayde |
director, officer: CEO |
76 CLIFF ROAD, BELLE TERRE NY 11777 |
| Wendy P. Smith |
10 percent owner |
P. O. BOX 1374, SALT LAKE CITY UT 84110 |
| Brett J. Earl |
director, officer: VP of Medical Marketing |
P.O. BOX 729, MORGAN UT 84050 |
| Mark Edward Christensen |
officer: CFO, Sec, Treas, Prin Acct Off |
455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111 |
| Thomas A Tait |
10 percent owner |
514 AMERICAS WAY #5556, BOX ELDER SD 57719 |
| Craig Morrison |
director, 10 percent owner, officer: Vice President of Technology |
975 NORTH TERRACE DRIVE, PROVO UT 84604 |
| William G Moon |
director, 10 percent owner, officer: Vice President of Operations |
1266 SOUTH 1380 WEST, OREM UT 84058 |
| Jeffrey Lynn Robins |
director, 10 percent owner, officer: CEO |
455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111 |
Nu-Med Plus (Nu-Med Plus) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUMD has been successfully added to your